Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus

López, Patricia; Rodríguez‐Carrio, Javier; Martínez-Zapico, Aleida; Pérez-Álvarez, Á.; Suárez‐Díaz, Silvia; Mozo, Lourdes; Benavente, Lorena; Caminal-Montero, Luis

doi:10.1093/rheumatology/keaa225

Cited by 7 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another unsolved issue is whether LDGs are indeed associated with CVD risks in patients with autoimmune or inflammatory diseases. Although LDGs are correlated with some risk factors of CVD in several cross-sectional or retrospective studies, the longitudinal data demonstrating the relation between LDGs and cardiovascular events is still unavailable [ 16 , 39 , 40 ]. The direct proof of LDGs infiltration in organ and tissue involvements remains absent as well [ 6 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…Calrucci et al reported that LDGs expressed a higher level of genes correlated with vascular inflammation and the noncalcified coronary plaque burden (NCB) in SLE patients, compared to NDNs [ 39 ]. Recently, López et al demonstrated that the ratio of CD16 − /CD14 − LDGs to high-density lipoprotein-cholesterol helped identify cardiovascular disease (CVD) risks [ 40 ]. Jointly, these findings suggest that LDGs have a key role in lupus activity and corresponding vascular damage.…”

Section: Role Of Ldgs In Immune-mediated Inflammatory Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases

Xin

Wang

Jin

2022

Journal of Immunology Research

View full text Add to dashboard Cite

Low-density granulocytes (LDGs), a distinct subset of neutrophils that colocalize with peripheral blood mononuclear cells after density gradient centrifugation, have been observed in many immune-mediated diseases. LDGs are considered highly proinflammatory because of enhanced spontaneous formation of neutrophil extracellular traps, endothelial toxicity, and cytokine production. Concomitantly, increased numbers of LDGs are associated with the severity of many immune-mediated inflammatory diseases. Recent studies, with the help of advanced transcriptomic technologies, demonstrated that LDGs were a mixed cell population composed of immature subset and mature subset, and these two subsets showed different pathogenic features. In this review, we summarize the current knowledge on the composition, origin, and pathogenic properties of LDGs in several immune-mediated inflammatory diseases and discuss potential medical interventions targeting LDGs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Role Of Ldgs In Immune-mediated Inflammatory Diseasesmentioning

confidence: 99%

Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases

Xin

Wang

Jin

2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Our group has demonstrated that IL-17 increases the expression of adhesion molecules and induces the adherence of T cells to human umbilical vein endothelial cells (HUVECs) (108). Another group found that Th17 cells contribute to atherosclerosis in SLE (117,118). Together, these studies suggest that IL-17 and Th17 cells may contribute to a vascular injury in an active SLE.…”

Section: Mirnas In Slementioning

confidence: 91%

miRNAs Alter T Helper 17 Cell Fate in the Pathogenesis of Autoimmune Diseases

Huang

Yang

2021

Front. Immunol.

View full text Add to dashboard Cite

T helper 17 (Th17) cells are characterized by the secretion of the IL-17 cytokine and are essential for the immune response against bacterial and fungal infections. Despite the beneficial roles of Th17 cells, unrestrained IL-17 production can contribute to immunopathology and inflammatory autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. Although these diverse outcomes are directed by the activation of Th17 cells, the regulation of Th17 cells is incompletely understood. The discovery that microRNAs (miRNAs) are involved in the regulation of Th17 cell differentiation and function has greatly improved our understanding of Th17 cells in immune response and disease. Here, we provide an overview of the biogenesis and function of miRNA and summarize the role of miRNAs in Th17 cell differentiation and function. Finally, we focus on recent advances in miRNA-mediated dysregulation of Th17 cell fate in autoimmune diseases.

show abstract

“…Total monocyte counts are increased in SLE patients showing clinical and subclinical CVD, but not in patients free of CVD. In 109 patients with disease longer than two years and 31 with earlier disease, total monocyte counts were increased compared to normal controls and patients' monocytes showed a more differentiated pattern, with a higher proportion of intermediate and non-classical monocytes, in direct correlation with higher IL-17 and IFN-I serum levels ( 139 ). The inflammatory milieu usually present in SLE patients may induce overactivation of monocytes, and their migration to the intima-media vascular layer, contributing to endothelial dysfunction ( 139 ).…”

Section: Immune Cellsmentioning

confidence: 99%

“…In 109 patients with disease longer than two years and 31 with earlier disease, total monocyte counts were increased compared to normal controls and patients' monocytes showed a more differentiated pattern, with a higher proportion of intermediate and non-classical monocytes, in direct correlation with higher IL-17 and IFN-I serum levels ( 139 ). The inflammatory milieu usually present in SLE patients may induce overactivation of monocytes, and their migration to the intima-media vascular layer, contributing to endothelial dysfunction ( 139 ). Monocytes produce intermediate mediators such as ROS and pro-inflammatory cytokines such as TNFα and IL-1β, building up endothelial damage through the vicious cycle of inflammation and oxidative stress.…”

Section: Immune Cellsmentioning

confidence: 99%

Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers

Guzmán‐Martínez

Marañón²

2022

Front. Immunol.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) patients display an increased risk of cardiovascular disease (CVD). With the improved clinical management of other classical severe manifestation of the disease, CVD is becoming one of the most relevant complications of SLE, and it is an important factor causing morbidity and mortality. Several immune constituents have been shown to be involved in the pathogenesis of atherosclerosis and endothelial damage in SLE patients, including specific circulating cell populations, autoantibodies, and inflammatory mediators. In this review, we summarize the presentation of CVD in SLE and the role of the autoimmune responses present in SLE patients in the induction of atherogenesis, endothelial impairment and cardiac disease. Additionally, we discuss the utility of these immune mediators as early CVD biomarkers and targets for clinical intervention in SLE patients.

show abstract

Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus

Cited by 7 publications

References 0 publications

Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases

Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases

miRNAs Alter T Helper 17 Cell Fate in the Pathogenesis of Autoimmune Diseases

Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers

Contact Info

Product

Resources

About